Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  docetaxel
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 912 for your search:
Start Over
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18530, NCT00127933
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_4001, NCT00280098
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC#08-002, IIT 12230, NCT00883675
A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML22780, 2009-014279-37, NCT01094184
A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 21 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOCET_L_04775, U1111-1116-9574, NCT01107756
Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25288, NCT01301729
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
Docetaxel in Head and Neck Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976F_2503, NCT00261703
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FLOT4, NCT01216644
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-08, NCT01348126
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: Over 18 to 70
Sponsor: Other
Protocol IDs: 91-03-33-18878, NCT01829178
Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-010, 2012-004391-19, 132355, NCT01905657
Phase III Randomized Study of High-Dose vs Low-Dose Docetaxel vs Standard Chemotherapy with Vinorelbine or Ifosfamide for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy (Summary Last Modified 08/97)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95088, RP-56976-TAX-320, NCI-V96-0830
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: EORTC-24971, RP-56976-V-323, NCT00003888
Start Over